Actinium Pharmaceuticals Provides Mid-Year Update Directed at Existing and Future Shareholders

  Actinium Pharmaceuticals Provides Mid-Year Update Directed at Existing and
  Future Shareholders

    Material Progress On All Fronts To Date in 2014 – Including: Pipeline
  Advances, Improved Stock Market Profile, Stronger Balance Sheet, Fortified
 Executive Team and Strong Support from Prominent Scientific Leaders – Leave
Company Well Positioned To Capitalize on The Promise of its Product Candidates

Business Wire

NEW YORK -- August 4, 2014

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"),
a biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, today provided a
Mid-Year Corporate Update to new and existing shareholders. The highlights
below underscore the significant progress that the Company has achieved on all
material fronts this year which leave it well positioned to execute on its
business plan and capitalize on the near-term promise of its core product
candidates Iomab™-B and Actimab-A.

Key Achievements in 2014

  *Enhanced Stock Market Profile with NYSE Markets Uplisting, Addition to the
    Russell® Indexes and Greater Trading Volume
  *Attracted Additional Research Analyst Coverage
  *Fortified Company Infrastructure with Key Executive Hires
  *Progression of Iomab™-B towards Phase 3 Clinical Trial
  *High-Profile Visibility and Support for Iomab™-B by Leading Experts
  *Advanced Actimab-A Phase 1/2 Program
  *Initiated Support for Third Development Program
  *Strengthened Balance Sheet

“Our team wishes to thank our existing shareholders for their faith in
Actinium this year.” stated Kaushik J. Dave, Ph.D., President and Chief
Executive Officer. “As can be clearly seen from the highlights of our
achievements listed above and elucidated below, we have made great progress
since our shareholder update in December 2013. However, we are acutely aware
that delivering on our primary objectives of bringing Iomab™-B to market in
2017 and establishing the clinical validity of Actimab-A for the treatment of
Acute Myeloid Leukemia (AML), requires us to meet nearer-term milestones on
time. I assure you that our entire team is energized and completely focused on
meeting our corporate objectives”.

ACHIEVEMENTS AND HIGHLIGHTS FOR 2014 YTD

  *Enhanced Stock Market Profile with NYSE Markets Uplisting, Addition to the
    Russell® Indexes, Greater Trading Volume Coverage and Research Analyst
    Coverage
    We successfully uplisted from the OTC bulletin board to the NYSE-MKT, a
    national exchange, in March 2014. This action enables a broader base of
    potential investors to invest in our strong future. We were privileged to
    join the broad-market Russell 3000® Index as well as the Russell 2000®,
    Russell Global and Russell Microcap® on June 27, 2014. These exchange and
    index inclusions coupled with our investor outreach efforts have resulted
    in greater than 12x improvement in liquidity (3-month average daily
    trading volume) since the last shareholder update in December 2013.
    Additional equity research coverage was initiated in July 2014 by
    Canaccord Genuity and featured a favorable rating and outlook for Actinium
    along the same line as the views of the existing Laidlaw analyst. We
    continue to extend our outreach efforts to buy and sell-side research
    analysts and portfolio managers in order to gain greater visibility and
    research coverage. We believe that our efforts should result in greater
    liquidity for our existing shareholders as appreciation of Actinium’s
    prospects with a wider audience takes hold and investor purchases
    increase.

  *Strengthened Balance Sheet and Fortified Company Infrastructure with Key
    Executive Hires
    We completed an underwritten secondary offering in June of 2014 which
    provided us $13.7 million and sufficient additional capital to fund our
    accelerated development activities with Iomab™-B and expand our clinical
    trial of Actimab-A for which we expect to release interim results by
    year-end. The strengthened balance sheet leaves the company with
    sufficient capital resources to meet our major near-term milestones which
    is of great comfort. Equally important, the potential inherent in our
    technology platform and core Iomab™-B and Actimab-A programs is further
    validated by our ability to attract top caliber, senior executives, each
    with more than 20-years of experience and prior success in the healthcare
    industry. The Team will play a critical role in ensuring that we meet or
    exceed our objectives across all key areas including Clinical Operations,
    Regulatory and Quality, Development, Investor and Public Relations, and
    Business Development.

  *Advanced Iomab™-B towards Phase 3 Clinical Trial
    Iomab™-B, the Company’s lead radioimmunotherapy asset, is on the cusp of
    entering a Pivotal Phase 3 trial to potentially address the significant
    unmet medical need for older patients who require less toxic conditioning
    prior to a bone marrow transplant. Since the last shareholder update, we
    have executed an agreement with ACT Oncology, a full-service, oncology
    focused, clinical research organization, to help us prepare and execute
    the Phase 3 clinical trial of Iomab™-B. We have started preparations for
    the trial, including centers recruitment feasibility study and outreach.
    In addition, we have worked diligently to put in place strong partners to
    ensure the highest quality manufacturing, labeling, and distribution of
    Iomab™-B to support both the clinical trial and potential
    commercialization. The necessary scale-up and validation for both the mAb
    and Iomab™-B finished drug product are currently at an advanced stage.
    Iomab™-B is a complex program and therefore we are making sure that we
    address all the requirements for not only a successful pivotal clinical
    study but also to ensure rapid regulatory approval and support commercial
    launch.

  *High-Profile Visibility and Support for Iomab™-B with Leading Experts
    We are pleased to report to our shareholders that the proof of concept
    data for Iomab™-B and the significant medical advance this drug candidate
    represents has attracted tremendous support from the thought leaders in
    bone marrow transplant. We are very pleased to be able to showcase their
    enthusiastic endorsement of Iomab™-B and our plans in a short three minute
    video we have posted on our web site  entitled  “Highlights from NY BIO
    Panel Discussion”. Please do take a look. We are humbled that we have been
    provided with the fantastic opportunity to be part of the development
    process that will bring such a lifesaving drug to patients who currently
    have no treatment options. In doing so, we will be well advised and
    supported by our recently constituted Iomab™-B Scientific Advisory Board
    which includes luminaries from some of the most prestigious cancer and
    transplant centers including: the Fred Hutchinson Cancer Research Center,
    Memorial Sloan Kettering Cancer Center, Case Western Reserve University,
    the Colorado Blood Cancer Institute, and Baylor Research Institute. This
    high-profile visibility and support is expected to significantly influence
    the medical community and enable Actinium to develop Iomab™-B to the
    fullest extent of its potential in AML and in several other blood cancers
    where it has shown promise.

  *Advanced Actimab-A Phase 1/2 Program and Initiated Support for a Third
    Development Program
    We continue to march forward with the Actimab-A Phase 1/2  trial and are
    on target to reveal interim results in December by the annual meeting of
    the American Society of Hematology, the preeminent scientific society for
    blood cancer research. We recently added Baylor Charles A. Sammons Cancer
    Center, one of the largest oncology centers in the nation treating over
    55,000 cancer patients every year, as a clinical trial site. They join
    several top US cancer centers including Memorial Sloan Kettering Cancer
    Center, MD Anderson Cancer Center, Fred Hutchinson Cancer Research Center,
    Johns Hopkins Medicine and University of Pennsylvania Health System. The
    addition of Baylor and other leading cancer centers with which we are in
    active discussions to join in the near future will support the ongoing
    enrolment in our Phase 1/2 study. Separately, we recently announced the
    development of another antibody-actinium-225 labeled construct to support
    a third clinical program at Memorial Sloan Kettering Cancer Center and
    will look to advance select additional programs where we already have a
    significant amount of both clinical and preclinical data.

“As plainly demonstrated above, we have been extremely busy this year
executing on our plans to deliver on the business plan for both the near-term
and longer-term”, stated Dr. Dave, “In the near-term, we expect to release
interim results on the Actimab-A trial in December and to begin the Iomab™-B
trial in the first half of 2015. Longer-term, we expect to deliver on our
primary objectives of bringing Iomab™-B to market in 2017 and establishing the
clinical validity of Actimab-A, as we seek to build an advanced, world-class
oncology company that can address challenges of many types of cancer. We are
confident our technologies can provide us with many potentially first-in-class
drugs to address unmet medical needs”.

“In conclusion,” stated Dr. Dave, “we are proud to report to our shareholders
that Team Actinium has made material progress on all fronts to date in 2014
including: pipeline advances, a much improved stock market profile, a stronger
balance sheet, a fortified executive team and high-profile support from
prominent scientific leaders. This progress, dear shareholders, leaves your
company well-positioned to capitalize on the promise of its product candidates
to deliver value. We thank-you once again for your support and hope that you
will be with us to share our future successes.”

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted
radiotherapy is based on its proprietary delivery platform for the therapeutic
utilization of alpha-emitting actinium-225 and bismuth-213 and certain
beta-emitting radiopharmaceuticals in conjunction with monoclonal antibodies.
The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing
patients for hematopoietic stem cell transplant, commonly referred to as bone
marrow transplant. The Company is preparing a single, pivotal, multicenter
Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid
Leukemia (AML) patients over the age of 55 with a primary endpoint of durable
complete remission. The Company’s second program, Actimab-A, is continuing its
clinical development in a Phase 1/2 trial for newly diagnosed AML patients
over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based
on management's current expectations and involve risks and uncertainties,
which may cause actual results to differ materially from those set forth in
the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA, +1 (646) 840-5442
VP Investor Relations and Finance
esmith@actiniumpharma.com
 
Press spacebar to pause and continue. Press esc to stop.